Sankaranarayanan, R.A.; Peil, J.; Vogg, A.T.J.; Bolm, C.; Terhorst, S.; Classen, A.; Bauwens, M.; Maurer, J.; Mottaghy, F.; Morgenroth, A.
Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230.
https://doi.org/10.3390/cancers14010230
AMA Style
Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A.
Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers. 2022; 14(1):230.
https://doi.org/10.3390/cancers14010230
Chicago/Turabian Style
Sankaranarayanan, Ramya Ambur, Jennifer Peil, Andreas T. J. Vogg, Carsten Bolm, Steven Terhorst, Arno Classen, Matthias Bauwens, Jochen Maurer, Felix Mottaghy, and Agnieszka Morgenroth.
2022. "Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study" Cancers 14, no. 1: 230.
https://doi.org/10.3390/cancers14010230
APA Style
Sankaranarayanan, R. A., Peil, J., Vogg, A. T. J., Bolm, C., Terhorst, S., Classen, A., Bauwens, M., Maurer, J., Mottaghy, F., & Morgenroth, A.
(2022). Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers, 14(1), 230.
https://doi.org/10.3390/cancers14010230